PRTN3 and rheumatoid arthritis: In fact, by studying only two different cellular targets and eight ACPA-positive RA patients, we could already identify four different scenarios: ACPAs targeting either osteoclasts or neutrophils, ACPAs targeting both cell types or neither of these.